ValiRx PLC
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ValiRx PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ValiRx PLC
LSE:VAL
Revenue
ÂŁ49.8k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-12%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Revenue
$51.1m
CAGR 3-Years
166%
CAGR 5-Years
99%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Revenue
ÂŁ310.2m
CAGR 3-Years
127%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Revenue
ÂŁ672.8m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
5%
Oxford BioMedica PLC
LSE:OXB
Revenue
ÂŁ151.2m
CAGR 3-Years
6%
CAGR 5-Years
18%
CAGR 10-Years
28%
No Stocks Found

ValiRx PLC
Glance View

Market Cap
3m GBX
Industry
Biotechnology

ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialization and partnering. The company is headquartered in Nuneaton, Warwickshire and currently employs 10 full-time employees. The company went IPO on 2000-02-28. The firm is engaged in the development of oncology therapeutics and companion diagnostics. The company focuses on the development of treatments in cancer and women’s health. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. Its VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer. Its VAL301 for the treatment of women with endometriosis. Its VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. Its BC201 is a combination of the peptide ingredient of VAL201 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. The company operates through divisional companies, including ValiPharma and ValiSeek.

VAL Intrinsic Value
0.08 GBX
Overvaluation 81%
Intrinsic Value
Price

See Also

What is ValiRx PLC's Revenue?
Revenue
49.8k GBP

Based on the financial report for Jun 30, 2025, ValiRx PLC's Revenue amounts to 49.8k GBP.

What is ValiRx PLC's Revenue growth rate?
Revenue CAGR 10Y
-12%

Over the last year, the Revenue growth was 419%.

Back to Top